Feedback and Inquiries.

Sam Mazin, Ph.D. and Akshay Nanduri founded RefleXion Medical in 2009.

The name dates back to 2008 from discussions between RefleXion’s founders, Sam Mazin, Ph.D. and Akshay Nanduri. They wanted to convey the source of the therapy as well as its capabilities. On the surface, the machine operates by “reflecting” gamma rays created by the accumulation of the PET tracer by the cancer cells back toward the tumor. It’s also the combination of the words “reflex” and “ion,” both important components of RefleXion technology. Specifically, PET emissions from cancer cells trigger immediate responses from the machine to destroy them with ionizing radiation, hence the suffix, “ion.” “Reflex” comes from the fact that the machine works in a fast, reflexive way. The capital X comes from the word X-ray, the source of the therapy.

RefleXion has raised over $200M in financing from a top-tier investment syndicate that includes pharmaceutical giants Pfizer and J&J.

The co-founders, Sam Mazin, Ph.D. and Akshay Nanduri have assembled an impressive internal team and advisory boards comprised of KOLs and renowned industry veterans. Todd Powell assumed the roles of president and CEO in 2017 after a successful leadership tenure with Elekta, one of the industry’s largest manufacturers of radiotherapy systems. In 2018, Martyn Webster joined the team as CFO bringing specific expertise in medical device startups and fundraising. To date, the company employs over 150 people, and is growing rapidly.

To reveal cancer as never before and beat it for everyone, everywhere.

To create a machine that combines biotargeting with radiation and enable the first-ever systemic reach for radiotherapy for patients with any stage of cancer.

Yes. In addition, you can also deliver cranial SRS and IMRT.

The RefleXion X1 is indicated for treatment planning and precise delivery of image-guided radiation therapy,
stereotactic radiotherapy, or stereotactic radiosurgery for tumors or other targeted tissues anywhere in the body.

The RefleXion X1 fits in most standard radiotherapy vaults and does not require additional shielding.

You will continue to use existing radiotherapy codes for treatment delivery and ancillary services for RefleXion X1.

Yes. Our table offers five degrees of freedom and the additional degree of freedom is gained with our rotating gantry.

Yes. The RefleXion X1 includes a premium couch top with indexing that allows for 3rd party immobilization devices.

Your contouring tools are compatible and the RefleXion X1 treatment planning system handles plan optimization and dose calculation.

The RefleXion X1 is equipped with BgRT components, but is currently cleared to deliver SBRT, SRS and IMRT. The RefleXion™ X1 is cleared for SBRT/SRS/IMRT treatments. BgRT is limited by U.S. law to Investigational use.

RefleXion BgRT (Biology-guided Radiotherapy) is the first machine designed to utilize the cancer itself to guide radiation delivery – even in tumors that are moving – to enable a leap forward in the ongoing goal of managing motion, reducing margins and diminishing toxicity, so that multiple tumors can be treated in the same session.

RefleXion’s BgRT uses PET – the gold standard in cancer imaging – in a novel way to solve the conundrum of tumor tracking. By transforming the use of PET from gradual image formation to instantaneous emission detection, BgRT aims to remove the uncertainty of guiding radiation delivery using images taken minutes, hours or even days before treatment. With PET emissions guiding treatment, the cancer itself acts as a fast, biological fiducial continuously signaling its location even during motion.

As the PET tracer accumulates in the tumor, a series of positron annihilation events occur resulting in the emission of two photons almost 180 degrees to each other. Their source – the tumor – can be localized along this straight line of coincidence, called a line of response, or LOR. The PET arcs on the RefleXion X1 machine detect the LORs and using that location information, immediately deliver a beamlet of radiation to the tumor to destroy it. This real-time response by the LINAC to detected PET emissions is the fundamental principle of BgRT.

There are two  major hurdles in radiotherapy today. The first is that tumors move with natural processes like breathing. This means that radiotherapy must meet the challenge of hitting a moving target accurately. The second obstacle is that normal tissues and organs are often located near tumors, which puts them at risk for bystander injury if the radiation is not delivered with millimeter precision.

To address these issues, complex plans and devices – including implanted fiducials — are often required to locate and deliver treatment to just one tumor with acceptable certainty. Therefore, in a patient with multiple tumors, the amount of time and effort required to treat the entire disease can become too burdensome to even attempt. This is one of the reasons that oncologists have not fully explored the use of radiotherapy in later stages of cancer, when tumors have spread to multiple locations in the body.

RefleXion is pending 510(k) clearance from the U.S. Food & Drug Administration (FDA). When we’re notified by the FDA that our machine has received 510(k) clearance, we will issue a public announcement.